by Companies Invest in Opiates and GABA-Related Compounds to Treat Cough Hypersensitivity Syndrome
On a global level, the alarming prevalence of chronic cough amongst individuals has propelled healthcare companies in the cough hypersensitivity syndrome treatment market to develop efficacious treatment options. As such, they are increasing their focus on developing improved formulations of antitussive agents. This trend is distinctly true, since antitussive agents are projected to dominate the cough hypersensitivity syndrome treatment market, with an estimated revenue of ~US$ 2.8 billion by 2027.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111768
In order to relieve patients from cough hypersensitivity, healthcare companies are investing in opiates and GABA (gamma-aminobutyric acid)-related compounds. Opiates serve as effective cough suppressants and possess efficacious antitussive properties to treat chronic intractable cough. Likewise, companies are increasing their production capabilities of tramadol, an opioid medication that is similar to the molecular formula of codeine drugs.
Since chronic cough causes increased body pain, companies in the cough hypersensitivity syndrome treatment market are increasing the availability of babapentin and pregabalin, which are GABA-related compounds, and act as neuromodulators for the treatment of neuropathic pain and epilepsy. It has been found in placebo-controlled trials that, gabapentin is well-tolerated for the treatment of refractory chronic cough.
PPI Therapy and Beta Agonists Provide Relief for GERD and Asthma
Healthcare companies in the cough hypersensitivity syndrome treatment space are increasing clinical trials to study the effects of aerosolized capsaicin with behavioral cough suppression. It has been found that, the inhalation of aerosolized capsaicin in gradually increasing doses has contributed to the decrease in cough sensitivity. Healthcare providers have recommended the repetition of the treatment sessions to effectively minimize the instances of cough hypersensitivity.
Chronic cough is associated with high prevalence of gastroesophageal reflux disease (GERD). Hence, companies in the cough hypersensitivity syndrome treatment market are innovating in proton pump inhibitors (PPI) therapy. Proton pump inhibitors currently account for the second-highest revenue share amongst the drugs in the cough hypersensitivity syndrome treatment market. PPI therapy is also effective for diseases related to GERD, such as achalasia, infectious esophagitis, and eosinophilic esophagitis. In order to treat asthma, healthcare providers in the cough hypersensitivity syndrome treatment market are increasing research capabilities in bronchodilators that include short acting beta-2 agonists. They also recommend patients to undergo spirometry to avoid the side effects of beta agonists.
Manufacturers Collaborating with Healthcare Providers to Increase Awareness about Early Upper Endoscopy
The cough hypersensitivity syndrome treatment market is anticipated to grow at a modest CAGR of ~5%. However, the nature of the market is consolidated, which makes it challenging for emerging market players to enter into the bracket of prominent and leading healthcare companies. Although the market is consolidated, the inefficiency of drugs and their adverse effects are negatively affecting market growth.
For instance, voltage-gated sodium channels reduce excitability and sensory nerve activity amongst patients. However, there is a growing need for newer agents that present realistic options for cough hypersensitivity syndrome patients. In many cases, proton pump inhibitors lead to complications of refractory GERD, with recurrence of reflux symptoms. Hence, healthcare companies in the cough hypersensitivity syndrome treatment market should increase awareness about the judicious administration of PPIs. They should team up with healthcare providers who can encourage patients to undergo early upper endoscopy to evaluate new alarm symptoms.
Analysts’ Viewpoint
New clinical guidelines by health commissions across nations suggest the screening, diagnosis, and treatment of chronic cough at regular intervals. Healthcare companies in the cough hypersensitivity syndrome treatment market should increase their research capabilities to understand pathophysiology for refractory chronic cough.
Antitussive agents are being increasingly used by healthcare providers to treat various complications of cough hypersensitivity. However, certain agents provide no clinical evidence of improvement in the health of patients. As such, there is an increasing need for the optimized clinical evaluation of uncontrolled symptoms and mechanistic understanding of neurobiology to achieve promising therapeutic targets. Market players should introduce more treatment options in anti-inflammatory therapy for patients with cough-variant asthma and eosinophilic bronchitis.
The cough hypersensitivity syndrome treatment market is projected to increase at a CAGR of 5.5%, from a value of ~US$ 7 Bn in 2018 to ~US$ 11 Bn by the year 2027.
A range of novel pharmacological approaches, such as P2X3 receptor antagonists (MK-7264) and other concepts are in clinical development for the treatment of cough hypersensitivity syndrome, which would contribute to the growth of the global cough hypersensitivity syndrome treatment market.
Cough hypersensitivity syndrome can be defined as a clinical entity in which excessive cough is experienced, triggered by lower levels of mechanical, thermal, and chemical exposure, and characterized by hypersensitivity reactions.
Cough hypersensitivity syndrome is caused due to a primary condition characterized by afferent neuronal hypersensitivity. Different aspects of this syndrome are manifested in various phenotypes of cough.
A variety of treatment options are available for cough hypersensitivity syndrome, depending upon the cause.
The treatment options for cough hypersensitivity syndrome include various drugs that majorly treat three most common causes: asthma, upper airway cough syndrome, and reflux conditions.
Antitussive agents are the common drugs used to treat cough hypersensitivity syndrome, owing to their effectiveness in treating cough, and ongoing related clinical trials.
All these factors are contributing to the growth of the global cough hypersensitivity syndrome treatment market.
Cough Hypersensitivity Syndrome Treatment Market: Drivers
Rise in the prevalence of chronic respiratory diseases is a major factor responsible for the growth of the global cough hypersensitivity syndrome treatment market.
Different respiratory diseases and conditions such as chronic obstructive pulmonary disease (COPD), asthma, and allergic rhinitis are some of the major conditions catalyzing the growth of the global cough hypersensitivity syndrome treatment market.
Increase in the number of smokers all around the world is a major contributor to the rise in chronic cough hypersensitivity syndrome and related disorders.
The high prevalence of unexplained chronic cough associated with Gastroesophageal Reflux Disease (GERD) is also fueling the growth of the global cough hypersensitivity syndrome treatment market.
Cough Hypersensitivity Syndrome Treatment Market: Segment Analysis
Increase in the usage of antitussive agents for the treatment of cough hypersensitivity and ongoing research on the development of effective antitussive therapies are leading to the growth of the antitussive agents drug class segment in the global cough hypersensitivity syndrome treatment market.
Retail pharmacies are major distribution channels for cough hypersensitivity syndrome treatment drugs. This segment dominated the global cough hypersensitivity syndrome treatment market in 2018, owing to an increase in the number of retail pharmacies in close vicinity to patients, as well as increasing sales of over-the-counter medication for cough treatment through these retail pharmacies.
The online pharmacies segment is a lucrative distribution channel segment in the global cough hypersensitivity syndrome treatment market. This is becoming a popular option for patients due to the convenience of online purchasing and numerous options available on online platforms for medicine and price comparison.
Cough Hypersensitivity Syndrome Treatment Market: Major Players
The report concludes with the company profiles section that includes key information about major players operating in the cough hypersensitivity syndrome treatment market.
Key players analyzed in this report on the global cough hypersensitivity syndrome treatment market are
- Pfizer, Inc.
- GlaxoSmithKline plc
- Boehringer Ingelheim GmbH
- AstraZeneca
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Merck & Co., Inc.
- Vertex Pharmaceuticals Incorporated
- Johnson & Johnson Consumer Inc.
Key Questions Answered in the Cough Hypersensitivity Syndrome Treatment Market Report
- What is the revenue expected to be generated by cough hypersensitivity syndrome treatment for each drug class across all regions during the forecast period?
- What are the opportunities in the global cough hypersensitivity syndrome treatment market?
- What are the major drivers, restraints, opportunities, and threats in the global cough hypersensitivity syndrome treatment market?
- Which regional market is likely to expand at the maximum CAGR during the forecast period?
- Which cough hypersensitivity syndrome treatment distribution channel is expected to generate the highest revenue, globally, in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
- What is the position of different companies operating in the global cough hypersensitivity syndrome treatment market?
Cough Hypersensitivity Syndrome Treatment Market – Segmentation
Drug Class
- Antitussive Agents
- Inhaled Corticosteroids
- Short Acting Beta-2 Agonists
- Anti-cholinergics
- Antihistamines
- Proton Pump Inhibitors
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111768/2900
